Legal status · Canada
Is Senolytic vaccine (anti-GPNMB) legal in Canada?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Senolytic vaccine (anti-GPNMB) is not approved for any medical use in Canada; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, no human study is cited on its profile.
Senolytic vaccine (anti-GPNMB) in Canada at a glance
| Classification | Investigational, not approved |
|---|---|
| Note | Preclinical. |
| Health Canada approval status | Not approved by Health Canada; investigational |
| Human studies cited | 0 of 3 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Senolytic vaccine (anti-GPNMB) profile, checked against Health Canada, Health Products and Food Branch (Health Canada) listings at the reviewed date.
What this means
- 01
Senolytic vaccine (anti-GPNMB) is being studied in registered clinical trials but has not received Health Canada marketing approval in Canada.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What Senolytic vaccine (anti-GPNMB) is
A vaccine that teaches the immune system to attack GPNMB, a protein enriched on senescent cells. In mice it removed GPNMB-positive cells and extended lifespan in male progeroid animals. There is no human trial.
A Japanese group at Juntendo and Niigata published this in Nature Aging in 2021 and the headline wrote itself: a vaccine against ageing. What they did is narrower and more interesting than the headline.
Mechanism: GPNMB is a transmembrane glycoprotein enriched on senescent cells, which makes it a seno-antigen: a surface tag the adaptive immune system can be trained to recognise. Vaccination raises antibodies and cellular immunity against GPNMB, so GPNMB-bearing cells are cleared by the immune system rather than by a drug.
Regulatory history: Not approved anywhere and not in any registered human trial. This is a mouse result published in the peer-reviewed literature, not a product.
How Health Canada treats this kind of product
Authorises drugs for sale through a Notice of Compliance and Drug Identification Number. A compound that is not authorised for sale cannot lawfully be sold for human use, and personal importation of prescription drugs is limited.
The classification above is the The Longevity Archive reading of Health Canada, Health Products and Food Branch listings for Senolytic vaccine (anti-GPNMB) at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Senolytic vaccine (anti-GPNMB) in other countries
United States
Not approvedInvestigational, not approved
Is Senolytic vaccine (anti-GPNMB) legal in the United States?United Kingdom
Not approvedInvestigational, not licensed
Is Senolytic vaccine (anti-GPNMB) legal in the United Kingdom?Australia
Not approvedInvestigational, not registered
Is Senolytic vaccine (anti-GPNMB) legal in Australia?Frequently asked questions
Is Senolytic vaccine (anti-GPNMB) legal in Canada?
No. Senolytic vaccine (anti-GPNMB) is not approved for any medical use in Canada; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, no human study is cited on its profile. Note: Preclinical.
Can I buy Senolytic vaccine (anti-GPNMB) in Canada?
No approved product exists to buy. In Canada Senolytic vaccine (anti-GPNMB) is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: Preclinical.
Is Senolytic vaccine (anti-GPNMB) Health Canada approved?
No. In Canada Senolytic vaccine (anti-GPNMB) is classified as "Investigational, not approved", which is not a Health Canada marketing approval. For comparison, the US FDA status is: Not approved anywhere and not in any registered human trial. This is a mouse result published in the peer-reviewed literature, not a product.. On the evidence, no human study is cited on its profile.
Related compounds in Canada
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Senolytic vaccine (anti-GPNMB) live on its compound profile.
Senolytic vaccine (anti-GPNMB) profileThis page is general information about the regulatory status of Senolytic vaccine (anti-GPNMB) in Canada, current as of Sep 2026. It is not legal advice, and classifications change; check Health Canada, Health Products and Food Branch directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.